甲基安非他明(Methamphetamine(The University of Montana)) - 药物靶点：adrenergic receptor_专利_临床

概要

基本信息

药物类型

小分子化药

别名

(+)-(S)-N-α-dimethylphenethylamine、(S)-N,α-dimethylbenzeneethanamine、(αS)-N,α-dimethylbenzeneethanamine

+ [14]

靶点

adrenergic receptor

作用机制

adrenergic receptor激动剂(肾上腺素能受体家族激动剂)、细胞凋亡抑制剂

治疗领域

神经系统疾病心血管疾病其他疾病

在研适应症-

非在研适应症

脑损伤脑卒中

原研机构

The University of Montana

在研机构-

非在研机构

Sinapis Group

Sinapis Pharma, Inc.

The University of Montana

最高研发阶段无进展临床1期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构/序列

分子式C10H15N

InChIKeyMYWUZJCMWCOHBA-VIFPVBQESA-N

CAS号537-46-2

关联

60

项与甲基安非他明相关的临床试验

ACTRN12624001263583

/ Not yet recruitingN/AIIT

The S-Check 2.0 cohort study: evaluating usage of a smartphone application to address methamphetamine use in adults

开始日期2024-10-21

申办/合作机构-

ChiCTR2400087191

/ Suspended早期临床1期IIT

Mechanisms of Repair of Brain Reward Functions in Male Methamphetamine Addicted Patients by Exercise Intervention

开始日期2024-08-01

申办/合作机构

东南大学附属中大医院

IRCT20221001056065N3

/ RecruitingN/AIIT

Investigating the effectiveness of transcranial electrical stimulation in preventing relapse in methamphetamine addicts

开始日期2024-07-21

申办/合作机构

Mashhad University of Medical Sciences

100 项与甲基安非他明相关的临床结果

登录后查看更多信息

100 项与甲基安非他明相关的转化医学

登录后查看更多信息

100 项与甲基安非他明相关的专利（医药）

登录后查看更多信息

13,127

项与甲基安非他明相关的文献（医药）

2025-06-01·Addictive behaviors reports

Do we need urine drug screens in opioid addiction treatment: An observational study on self-report versus urine drug screens

Article

作者: Worster, Andrew ; Marsh, David C ; Dennis, Brittany B ; Thabane, Lehana ; Rodrigues, Myanca ; McEvoy, Alannah ; Samaan, Zainab ; Hudson, Jacqueline

Background:

The substance use crisis continues to progress. Medication for Opioid Use Disorder (MOUD) are prescribed to reduce opioid use and related harms; however, many individuals continue to use substances while on treatment. The objective of this study was to describe the temporal and demographic trends of the agreement between self-reported and urine tested substances.

Methods:

The current study is a retrospective secondary analysis of three phases of a prospective cohort study (Pilot 2011, Genetics of opioid addiction (GENOA) 2013-2017, and Pharmacogenetics of opioid substitution treatment (POST)) 2018-2022) spanning 2011-2022. We compared the self-reported substance use data for opioids, benzodiazepines, amphetamine/methamphetamine (AMP/MET), and cocaine with urine drug results. We compared the positive predictive value (PPV), false omission rate (FOR), sensitivity, and specificity between (i) different drugs; (ii) by sex, and (iii) age group at enrollment in each phase of the study using self-reported substance use at baseline and retrospective electronic health record data on urine drug screenings collected over the same time period.

Results:

Overall, the average PPV and FOR for any drug across all phases was 80.7 % and 37.9 %, respectively. Sensitivity and specificity were highest for cocaine and lowest for benzodiazepines. We found no specific trend by sex. Lastly, we found a higher sensitivity for opioids and AMP/MET in those under 25 years of age compared to other age groups. PPV increased over time for benzodiazepines, AMP/MET and cocaine and FOR was higher during the pilot and POST phases than the GENOA phase.

Conclusion:

Our study highlights the unique challenges associated with ascertaining substance use behaviour for individuals receiving MOUD, indicating many patients will accurately report substance use while others do not. It is therefore important to consider the context of the patient, and the type of the co-substance used to select patient-centred testing as indicated. Therefore, the answer to the question of do we need urine drug screen is yes in some cases.

2025-03-01·HEART & LUNG

Methamphetamine-associated heart failure: Clinical characteristics and outcomes in a safety net population

Article

作者: Win, Sithu ; Thakkar, Anjali B ; Ma, Yifei ; Durstenfeld, Matthew S ; Hsue, Priscilla Y

BACKGROUND:

Methamphetamine use is increasing and is associated with development of heart failure (HF). However, clinical characteristics and outcomes have not been well-described.

OBJECTIVE:

To compare outcomes among individuals with HF with and without methamphetamine use in a safety-net setting.

METHODS:

This retrospective matched cohort study included individuals with HF with history of methamphetamine use and age, gender-, and year-matched controls without history of methamphetamine use in a municipal health system from 2001 to 2019. One thousand seven hundred seventy-one individuals with methamphetamine use and HF and 3,542 age, sex, and year-of-HF-diagnosis matched controls with HF without methamphetamine use were included. The primary outcome was all-cause mortality. Secondary outcomes included time to HF hospitalization, 30-day, 90-day, and one-year HF, and all-cause readmissions.

RESULTS:

The median age of the cohort was 52.1 years and 22.6 % were female. Black/African American was the most common racial identity (methamphetamine: 49.1 %; no methamphetamine: 33 %). There was no significant difference in mortality between groups (40% vs 36.6 %,HR 1.00,95 % CI 0.91,1.10,p = 1.00). A subset had an index HF hospitalization (n = 1,404, 26.4 %) during the study period, including 637 (35.9 %) with history of methamphetamine use and 767 (21.7 %) without history of methamphetamine use (relative risk 1.66,95 % CI 1.52-1.81,p < 0.0001). Among those who were ever hospitalized for HF, individuals with methamphetamine use had increased risk of HF and all-cause readmission at 30 days (RR 1.92,95 % CI 1.36-2.70,p < 0.001), 90 days (RR 1.69,95 % CI 1.35-2.12,p < 0.001), and one year (RR 1.61,95 % CI 1.36-1.91,p < 0.001).

CONCLUSION:

Despite having higher all-cause and HF readmission risk, individuals with methamphetamine-associated HF did not have higher mortality risk.

2025-03-01·BURNS

A prospective, historical-controlled evaluation of oliceridine for moderate or severe pain in patients with acute burn injuries (RELIEVE)

Article

作者: Hill, David M ; Todor, Lorraine A

Oliceridine, a biased, selective opioid agonist, has shown a 3-fold preferential activation of the G-protein (i.e., analgesia) over β-arrestin pathway. β-arrestin activation is believed to be associated with higher adverse events, such as constipation, respiratory depression, and desensitization. There is no literature of use in patients with burn injuries. We hypothesized the use of oliceridine would provide adequate and safe analgesia after acute burn injury. Ten patients received oliceridine as their sole opioid for up to 7 days, which was compared to a random, historical cohort receiving standard of care (i.e, fentanyl, oxycodone, hydromorphone, and morphine). The historical control group was initially matched 2:1 (though 2 patients were ultimately excluded) with the oliceridine group according to age, percent total body surface area burned (TBSA), and number of operations. No patient had a history of known opioid, cocaine, or methamphetamine use, as this was an exclusion criterion for the prospectively enrolled group. Baseline numerical rating scale (NRS) was similar for both groups [9 (7.8, 10) vs 9.5 (8.8, 10); p = 0.360). Over the 7-day period, mean daily pain scores significantly decreased in both groups. However, use of oliceridine was associated with a significantly larger decrease in mean pain score [-0.74 (-1.36, -0.12), p = 0.0215]. There was no difference in average daily morphine milligram equivalents (MME) [-14.02 (-67.22, 39.19), p = 0.5939]. There were no unexpected adverse events related to oliceridine. Oliceridine demonstrated significant pain relief, which was maintained over the 7-day study period. The control group demonstrated initial relief, which was not maintained despite similar MME.

140

项与甲基安非他明相关的新闻（医药）

2025-01-14

·GlobeNewswire-Health Care

Intelligent Bio Solutions Partners with Princebuild to Transition from Saliva Testing to Fingerprint Sweat-Based Drug Screening Across its Seven UK Sites

Princebuild joins INBS’ portfolio of over 400 accounts in 19 countries as the Company plans to enter the US market in the first half of the 2025 calendar yearNEW YORK, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that Princebuild, a leading construction firm with seven sites and operations spanning six key divisions, has adopted INBS’ Intelligent Fingerprinting Drug Screening System. Princebuild has made a strategic decision to move from saliva testing to fingerprint drug screening in order to implement a more streamlined, in-house solution that prioritizes efficiency, accuracy, and respect for employee privacy. Princebuild, an established construction company in Peterborough, Cambridgeshire, UK and its surrounding areas, has integrated INBS' fingerprint sweat-based technology to enhance safety and compliance across its workforce. The system's simplicity, ease of use, and shorter detection window will enable Princebuild to conduct fast, reliable testing while respecting employees' personal lifestyles. "By adopting Intelligent Bio Solutions fingerprint sweat-based system, we have transformed our approach to workplace testing," said Cheryl Browne, Human Resources Support Manager at Princebuild. "We wanted a method that ensured safety in our workplace without feeling like we were policing our employees' lifestyles. The simplicity and efficiency of this solution aligns with our company values." Princebuild joins other leading construction companies that utilize INBS’ innovative drug-testing technology, including Mount Anvil, Hayfield Homes, Stonbury, MBP Structures, and PJ Hegarty & Sons U.K. Ltd. These companies employ INBS’ technology to proactively address substance misuse in the workplace by focusing on ensuring employees are fit for duty at the time of testing. INBS’ Intelligent Fingerprinting Drug Screening System allows organizations to implement an accurate and efficient testing protocol that meets the needs of the modern workforce. With its ability to detect multiple substances simultaneously and provide rapid results, the system eliminates many challenges associated with traditional testing methods, allowing businesses like Princebuild to focus on cultivating safer, more productive workplaces. The Company has over 400 accounts across 19 countries. Its Drug Testing Solution is currently being utilized across multiple industries, including construction, mining, manufacturing and engineering, transport and logistics, drug treatment, law enforcement, and forensics. With recent FDA 510(k) submission in December of 2024 and entry into the US market planned for the first half of calendar year 2025, INBS is capitalizing on the rapidly growing drug screening products market. About Princebuild Princebuild Limited has cared for, maintained, and built properties since 1971. The company specializes in delivering diverse construction services through six key divisions: construction, small works, insurance, maintenance, building services, and commercial interiors. Over the years, Princebuild has expanded its operations to serve the entire East of England and provides national coverage for larger projects. About Intelligent Bio Solutions Inc. Intelligent Bio Solutions Inc. (NASDAQ: INBS) is a medical technology company delivering innovative, rapid, non-invasive testing solutions. The Company believes that its Intelligent Fingerprinting Drug Screening System will revolutionize portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields. Designed as a hygienic and cost-effective system, the test screens for the recent use of drugs commonly found in the workplace, including opiates, cocaine, methamphetamine, and cannabis. With sample collection in seconds and results in under ten minutes, this technology would be a valuable tool for employers in safety-critical industries. The Company's current customer segments outside the US include construction, manufacturing and engineering, transport and logistics firms, drug treatment organizations, and coroners. For more information, visit: http://www.ibs.inc/ Forward-Looking Statements: Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, Intelligent Bio Solutions Inc.'s ability to successfully develop and commercialize its drug and diagnostic tests, realize commercial benefit from its partnerships and collaborations, and secure regulatory approvals, among others. Although Intelligent Bio Solutions Inc. believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Intelligent Bio Solutions Inc. has attempted to identify forward-looking statements by terminology, including "believes," "estimates," "anticipates," "expects," "plans," "projects," "intends," "potential," "may," "could," "might," "will," "should," "approximately" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, included in Intelligent Bio Solutions' public filings filed with the Securities and Exchange Commission. Any forward-looking statements contained in this release speak only as of its date. Intelligent Bio Solutions undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events. Company Contact: Intelligent Bio Solutions Inc. info@ibs.inc LinkedIn | Twitter Investor & Media Contact: Valter Pinto, Managing Director KCSA Strategic Communications PH: (212) 896-1254 INBS@kcsa.com

2024-12-19

·drugs

U.S. Life Spans Rebound from Pandemic Lows, Helped by Drop in Fatal Overdoses

THURSDAY, Dec. 19, 2024 -- After years of decline, U.S. life expectancy is finally on the rise again for the first time since 2019, new government research shows. This turnaround was driven in part by a decline in drug overdose deaths, which had risen dramatically as a result of the opioid epidemic, according to a second report from the U.S. Centers for Disease Control and Prevention. That includes the first reduction in OD deaths caused by powerful synthetic opioids like fentanyl and tramadol, researchers said. “The age-adjusted rate for drug overdose deaths involving synthetic opioids other than methadone decreased from 2022 to 2023, the first such decrease since the large increases that began in 2013,” concluded the research team led by Matthew Garnett , an injury epidemiologist and statistician with the CDC’s National Center for Health Statistics (NCHS). “The rate also decreased for deaths involving natural and semisynthetic opioids and heroin between 2022 and 2023,” the team added. Life expectancy at birth in 2023 was 78.4 years for the total population, an increase of 0.9 years from 77.5 in 2022, CDC researchers reported. For men, life expectancy increased 1 year, from 74.8 in 2022 to 75.8 in 2023. Meanwhile, women saw a 0.9-year increase, from 80.2 in 2022 to 81.1 in 2023. “From 2022 to 2023, age-adjusted death rates decreased for 9 of the 10 leading causes of death,” wrote the life expectancy research team led by Elizabeth Arias , a health scientist with the NCHS. Deaths due to heart disease, accidental injury, stroke, respiratory disease, Alzheimer’s disease, diabetes, kidney disease, liver disease and COVID-19 all fell significantly between 2022 and 2023, researchers found. The rate of cancer deaths also went down, but not significantly, the report says. The end of the pandemic likely contributed to the increase in life expectancy, researchers said. “The most notable change was for COVID-19, which dropped from the 4th leading cause in 2022 to the 10th leading cause in 2023,” the researchers wrote. Overall, COVID deaths decreased more than 73% between 2022 and 2023, falling from 44.5 deaths to 11.9 deaths per 100,000, researchers said. A decrease in drug OD deaths also contributed to improved life expectancy. The rate of drug overdose deaths fell from 32.6 per 100,000 in 2022 to 31.3 per 100,000 in 2023, researchers said. Drug OD deaths are considered accidental injury deaths. These results jibe with statistics released last week by the CDC, which reported that drug OD deaths had decreased 17% between July 2023 and July 2024. However, the OD death rate is still 3.5 times what it was in 2003, when 8.9 people for every 100,000 died by drug overdose. Drug OD deaths related to synthetic opioids declined by 2.2% between 2022 and 2023, results show -- the first significant decline in OD deaths related to synthetic opioids like fentanyl since 2003, researchers added. Drug overdose deaths related to natural opioids like morphine, oxycodone and hydrocodone also declined 17.1%, between 2022 and 2023, and OD deaths caused by heroin decreased 33.3%. However, OD death rates for cocaine increased by 4.9% between 2022 and 2023, and OD deaths from stimulants like methamphetamine increased by 1.9%, researchers said. Lastly, infants did not seem to benefit from the declining death rates, researchers found. “The infant mortality rate of 560.2 infant deaths per 100,000 live births in 2023 was not significantly different from the rate in 2022,” the researchers wrote. The ten leading causes of infant death in 2023 -- birth defects, low birth weight, sudden infant death syndrome, unintentional injuries, maternal complications, bacterial sepsis of newborn, cord and placental complications, respiratory distress of newborn, intrauterine hypoxia and birth asphyxia, and diseases of the circulatory system -- accounted for more than 65% of all infant deaths, researchers concluded. Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

2024-12-10

·Business Wire

Aegis Sciences Corporation Announces Updates for NPS Testing

NASHVILLE, Tenn.--( BUSINESS WIRE )-- Aegis Sciences Corporation , a health care testing lab based in Nashville, TN, is pleased to announce the second bi-annual update to its novel psychoactive substance (NPS) testing menu. Aegis regularly updates its testing menu based on recommendations established collaboratively by the Center for Forensic Science Research and Education (CFSRE) and the Society of Forensic Toxicologist (SOFT) NPS Committee. Updates to the testing menu include CFSRE’s tier one and tier two scope recommendations for Quarter 3 of 2024. “Aegis is committed to staying current by developing definitive analytical methods that can detect new compounds that reflect actual drug use trends in the market,” said Dr. Rebecca Heltsley, Senior Vice President, Research and Development at Aegis Sciences Corporation. Aegis’s NPS testing menu is reviewed regularly to augment the offering in a manner that allows it to maintain clinical relevance. Updates will include o/m/p-Methylfentanyl, a fentanyl analog that has recently been identified as circulating at a greater frequency, N-Isopropyl Butylone, a substituted cathinone that has been detected in illicit drug material with methamphetamine, and phenylbutazone, a nonsteroidal anti-inflammatory drug removed from the pharmaceutical market that is being found as an adulterant in the illicit drug supply. “High-risk substances that are in circulation are ever-changing, and through the use of Aegis’s definitive testing, clinicians are able to refine and improve harm reduction and overdose prevention strategies,” said Dr. Josh Schrecker, Sr. Dir. of Clinical Affairs at Aegis Sciences Corporation. “This update is tangible proof of our commitment that we will continue to provide our clients with the best tools available to achieve a clear understanding of the illicit substance impacting their communities and to manage risk,” said Dr. Frank Basile, CEO of Aegis Sciences Corporation. Health care practitioners can learn more about the updated test offering through the Aegis website: https://www.aegislabs.com/services/novel-psychoactive-substances/ About Aegis Sciences Corporation Founded in 1990, Aegis Sciences Corporation is a laboratory sciences company based in Nashville, Tenn., that provides science-driven testing and consulting services for clients such as health care providers, pharmaceutical companies, professional and amateur sports organizations, leading college and university athletic programs, Fortune 500 corporations, and government agencies throughout the United States. For more information, please visit http://www.aegislabs.com/ .

100 项与甲基安非他明相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D08187	甲基安非他明	N06BA03	DB01577

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
脑损伤	临床1期	美国	Sinapis Pharma, Inc.	-
脑损伤	临床1期	-	The University of Montana	-
脑损伤	临床1期	-	Sinapis Group	-
脑卒中	临床1期	美国	Sinapis Pharma, Inc.	-
脑卒中	临床1期	-	The University of Montana	-
脑卒中	临床1期	-	Sinapis Group	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04642820 (DDP, CTgov)	早期临床1期	-	138	placebo oral tablet+Methamphetamine (Placebo Then Methamphetamine)	壓壓鏇構廠鏇積製製窪(壓遞積憲遞鑰選鑰鏇醖) = 鹹襯鏇積願膚簾遞簾觸廠糧鑰築願艱鬱餘鑰憲 (鹹築獵願積糧範廠蓋範, 衊憲糧壓艱衊顧範築願 ~ 憲構膚餘淵餘繭網遞鏇) 更多	-	2025-01-09
				placebo oral tablet+Methamphetamine (MethamphetamineThen Placebo)	壓壓鏇構廠鏇積製製窪(壓遞積憲遞鑰選鑰鏇醖) = 構願壓淵餘遞繭窪醖積廠糧鑰築願艱鬱餘鑰憲 (鹹築獵願積糧範廠蓋範, 蓋淵簾憲鏇憲範壓窪膚 ~ 憲齋壓艱醖繭顧構鹹觸) 更多
ATS2024	N/A	肺动脉高压	-	Continued Methamphetamine Usage	鑰範憲窪夢簾網艱鬱鑰(艱築積艱網築餘願構膚) = 繭糧艱醖齋鏇衊構窪齋簾範鹽鑰蓋築餘蓋齋網 (憲遞選製蓋鏇襯憲築壓 )	-	2024-05-19
				Abstinence from Methamphetamine	鑰範憲窪夢簾網艱鬱鑰(艱築積艱網築餘願構膚) = 淵構簾範網壓鏇廠獵淵簾範鹽鑰蓋築餘蓋齋網 (憲遞選製蓋鏇襯憲築壓 )
NCT03790618 (ESP, CTgov)	临床1期	-	36	3,4-Methylenedioxymethamphetamine+methamphetamine (Placebo)	範選簾築鏇夢廠鹽餘齋(顧憲鑰網廠壓鬱齋範鹹) = 繭艱蓋鹽築築鑰鹹觸餘鏇鏇願構夢襯壓鹹餘簾 (鹽獵範積選築遞餘繭鬱, 壓製鑰範憲蓋鏇壓顧顧 ~ 鑰憲夢廠醖壓廠窪壓鹽) 更多	-	2024-01-05
				3,4-Methylenedioxymethamphetamine+methamphetamine (Low Dose MDMA)	範選簾築鏇夢廠鹽餘齋(顧憲鑰網廠壓鬱齋範鹹) = 鏇鹽遞衊鹹餘醖繭壓襯鏇鏇願構夢襯壓鹹餘簾 (鹽獵範積選築遞餘繭鬱, 積鹹蓋齋構糧衊壓鏇繭 ~ 廠鏇觸壓積醖憲獵鬱夢) 更多
NCT04178993 (CTgov)	临床1期	甲基苯丙胺依赖	8	Placebo oral capsule+Methylphenidate+Methamphetamine (Placebo Comparator: Placebo)	願鏇壓衊鏇製鹽襯範顧(膚願積艱顧築餘構製糧) = 糧鏇蓋鹽鹹齋遞鬱齋艱窪蓋夢遞糧齋願憲壓憲 (獵顧膚願遞鏇衊鏇窪選, 襯餘艱醖觸夢觸範鹹衊 ~ 餘鹽醖憲積願構壓築壓) 更多	-	2023-01-09
				Placebo oral capsule+Methylphenidate+Duloxetine+Methamphetamine (Active Comparator: Duloxetine)	餘願顧遞獵鬱鏇鹹壓廠(簾願蓋糧衊夢窪顧壓鹽) = 衊築夢鬱淵願鏇製鹹窪築鏇積製範願齋願艱襯 (鏇糧鏇願壓簾餘築夢憲, 網齋醖襯願餘網鏇網選 ~ 觸積願衊艱蓋襯築繭齋) 更多
ATS2021	N/A	继发性肺动脉高压	-	Active Methamphetamine Use	艱餘鬱鏇齋餘鹹築餘鹹(壓鬱鹹夢鹹顧淵選顧窪) = 網窪蓋糧獵繭壓築積蓋網網築選憲壓鏇膚醖範 (鬱獵顧窪憲鑰鑰遞鏇窪 ) 更多	-	2021-05-03
				Abstaining from Methamphetamines	艱餘鬱鏇齋餘鹹築餘鹹(壓鬱鹹夢鹹顧淵選顧窪) = 窪窪壓積願簾淵衊鹹蓋網網築選憲壓鏇膚醖範 (鬱獵顧窪憲鑰鑰遞鏇窪 ) 更多
ESC2019	N/A	扩张型心肌病	-	methamphetamine	網積構製顧築夢夢鹹餘(餘膚鬱餘醖鹹糧蓋觸蓋) = 鏇糧網網餘廠鏇齋鹽餘餘蓋醖廠鹽簾醖餘膚醖 (襯窪觸餘觸廠鹹網鑰衊 ) 更多	-	2019-09-02
ISC2019	N/A	脑出血 methamphetamines	596	Patients with UDS for methamphetamines	鬱餘築憲衊選糧顧壓膚(餘網製廠網壓蓋憲積鹹) = 選襯憲鬱遞範鹽網鬱鏇鹹鹹簾艱選構淵糧艱淵 (鏇構鏇範窪廠獵艱鏇鏇 )	-	2019-02-01
				Patients without UDS for methamphetamines	鬱餘築憲衊選糧顧壓膚(餘網製廠網壓蓋憲積鹹) = 窪觸遞鏇遞窪襯壓鏇餘鹹鹹簾艱選構淵糧艱淵 (鏇構鏇範窪廠獵艱鏇鏇 )
NCT02323048 (CAM, CTgov)	N/A	物质滥用	90	placebo+methamphetamine (Paired, Low Reward)	糧繭齋憲醖鑰襯獵憲餘(鬱蓋繭遞衊繭鏇鏇蓋壓) = 製觸襯齋醖鹽鑰鏇簾蓋顧餘範顧餘醖遞構鬱醖 (膚網願壓簾構襯鹹範壓, 齋鹽觸選簾簾鏇簾鏇選 ~ 鬱築糧夢獵廠蓋製壓繭) 更多	-	2018-07-26
				placebo+methamphetamine (Paired, High Reward)	糧繭齋憲醖鑰襯獵憲餘(鬱蓋繭遞衊繭鏇鏇蓋壓) = 鏇艱壓獵憲蓋壓蓋艱糧顧餘範顧餘醖遞構鬱醖 (膚網願壓簾構襯鹹範壓, 簾廠鏇窪襯製齋獵繭夢 ~ 餘夢積簾築衊鏇膚製艱) 更多
MDS2017	N/A	-	-	Methamphetamine users (males)	醖獵膚壓網糧餘壓顧獵(願製窪膚獵鹽憲艱鏇鹽) = 鏇製獵糧鑰網廠網簾艱壓繭鏇積窪製蓋壓鏇廠 (淵膚鬱鏇蓋廠遞糧餘積 )	-	2017-06-04
				Methamphetamine users (females)	醖獵膚壓網糧餘壓顧獵(願製窪膚獵鹽憲艱鏇鹽) = 築簾範選糧淵壓顧遞艱壓繭鏇積窪製蓋壓鏇廠 (淵膚鬱鏇蓋廠遞糧餘積 )
AAN2017	N/A	脑出血 methamphetamine positive toxicology screen	-	methamphetamine	醖膚襯獵衊糧夢淵簾壓(網襯範鏇觸獵觸鹽艱衊) = 壓選淵範築構蓋獵廠遞淵餘艱蓋觸製鏇餘夢鏇 (襯襯淵膚積淵鑰顧窪齋 )	积极	2017-04-18